Polyrizon opened lower at $10.50, compared with its previous close of $11.02. In the last trading session, the stock traded between $10.00 and $11.04. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Polyrizon is now worth
$ 0.49
Resulting in a loss of
$ 99.51 (99.51%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.41 (+3.70%)
Day High
$11.04
Day Low
$10.00
Day Open
$10.50
Prev Close
$11.02
Volume
18,527
1W Return
1.58%
1M Return
24.02%
3M Return
13.21%
6M Return
-29.13%
1Y Return
123.73%
Fundamentals
Market Cap ($ Mn)
27
PE Ratio
-
PB Ratio
1.01
PEG Ratio
-
ROE
-22.41%
ROCE
-24.89%
EPS (TTM)
-
Investment Returns
1 Week
1.58%
1 Month
24.02%
3 Months
13.21%
6 Months
-29.13%
9 Months
-11.09%
Financials
Quarterly
All values in $ Mn
No data available.
Updates
27Oct
Polyrizon completes enrollment for US trial of nasal hydrogel NASARIX
Completed patient enrollment and randomization for the U.S. multicenter study of NASARIX. Randomized 120 participants across five clinical research sites in the United States. Screened a total of 144 individuals to achieve the planned enrollment target.
16 days ago
2Sep
Polyrizon completes all five US site contracts for NASARIX allergy study
Polyrizon completed contracting with all five US clinical sites for its first-in-human NASARIX study. The trial aims to enroll up to 120 patients with seasonal allergic rhinitis in a randomized design. Patients will be split 1:1 between NASARIX Allergy Blocker and saline control groups. Enrollment timing will align with seasonal allergen exposure based on pollen counts.
2mo ago
10Jun
Polyrizon secures European patent for nasal drug delivery tech
Polyrizon Ltd. announced the European Patent Office (EPO) has completed technical preparations for the publication of its European patent application, titled "Mucoadhesive Polymers for Nasal Drug Delivery," under publication number EP 4751737. The patent covers the proprietary Trap & Target (T&T) mucoadhesive polymer technology platform, designed to enhance formulation retention and drug absorption through the nasal route. The company aims to strengthen its intellectual property portfolio to support future pharmaceutical applications and collaborations.
